Talphera

TLPH · NASDAQ

$1.07−$0.01 (−0.93%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $1.08

TLPH analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $3.23 (+201.9% upside)

Low: $3.03
Now: $1.07
High: $3.67

Upgrades and downgrades

The latest rating actions, newest first

TLPH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Jun 5, 2026	Initiates	Buy	$3.00	36%
WestPark Capital	Apr 30, 2026	Initiates	Buy	$3.00	47%

The case for and against

Updated Feb 6, 2025

Bull case

Talphera Inc. has achieved a significant milestone with FDA approval to increase the maximum number of study sites from 10 to 14, which is anticipated to expedite the enrollment process for their NEPHRO CRRT study, targeting 166 patients. The ongoing collaboration with eight original large academic institutions is expected to enhance trial recruitment, as some institutions are projected to be among the highest enrollers. Moreover, Talphera's planned protocol modifications and the intention to submit a Prior Approval Supplement to adjust the patient requirement demonstrate a strategic approach toward fulfilling regulatory obligations and achieving study completion by year-end 2025.

Bear case

Talphera Inc. reported a net loss of $3.8 million for the second quarter of 2024, translating to a loss of $0.15 per share, reflecting ongoing financial challenges. The company’s decision to lower its 2024 operating expense guidance to a range of $19-$21 million from the previous $21-$23 million suggests difficulties in managing costs amidst mounting losses. Additionally, significant risks related to trial outcomes, FDA approvals, safety concerns, and funding acquisition pose further threats to the company's financial stability and growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.